Esperance: Harmonizing hormones to cancer

Based on a technology invented at Louisiana State University as a means of sterilizing animals, Esperance Pharmaceuticals Inc. is developing fusion proteins that combine a tumor-seeking hormone receptor ligand and a cytotoxin to treat cancer. Next quarter, the company plans to start a Phase I trial of EP-100, which incorporates a cytotoxic peptide that may avoid resistance mechanisms because it causes tumor cell death without needing to be internalized.


Read the full 694 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers